董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stuart Holden | 男 | Director | 82 | 18.64万美元 | 未持股 | 2025-08-26 |
| Elizabeth Barrett | 女 | President, Chief Executive Officer and Director | 63 | 414.99万美元 | 未持股 | 2025-08-26 |
| Cynthia M. Butitta | 女 | Director | 71 | 19.39万美元 | 未持股 | 2025-08-26 |
| James A. Robinson, Jr | 男 | Director | 55 | 18.39万美元 | 未持股 | 2025-08-26 |
| Leana S. Wen | 女 | Director | 42 | 19.64万美元 | 未持股 | 2025-08-26 |
| Daniel Wildman | 男 | Director | 69 | 19.43万美元 | 未持股 | 2025-08-26 |
| Daniel G. Wildman | 男 | Director | 69 | 未披露 | 未持股 | 2025-08-26 |
| Arie Belldegrun | 男 | Chair of the Board | 75 | 33.19万美元 | 未持股 | 2025-08-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Chris Degnan | 男 | Chief Financial Officer | 45 | 105.38万美元 | 未持股 | 2025-08-26 |
| Elizabeth Barrett | 女 | President, Chief Executive Officer and Director | 63 | 414.99万美元 | 未持股 | 2025-08-26 |
| Mark P. Schoenberg | 男 | Chief Medical Officer | 68 | 未披露 | 未持股 | 2025-08-26 |
| Jason Smith | 男 | General Counsel and Chief Compliance Officer | 53 | 127.55万美元 | 未持股 | 2025-08-26 |
| Chris Degnan | 男 | Chief Financial Officer | 46 | 未披露 | 未持股 | 2025-08-26 |
董事简历
中英对照 | 中文 | 英文- Stuart Holden
-
Stuart Holden自2015年12月起担任我们的董事。自ProQuest Investments’；Scientific Advisory Board于1998年成立以来，Holden博士一直担任其董事长。自2014年5月起，Holden博士担任UCLA教员，担任泌尿外科健康科学临床教授，Spielberg家族泌尿肿瘤学主席，在加州大学洛杉矶分校大卫·格芬医学院泌尿外科和加州大学洛杉矶分校泌尿肿瘤研究所副主任。Holden博士在前列腺癌领域工作了超过36年。自1993年前列腺癌基金会成立以来，Holden博士还担任该基金会的医学总监。Holden博士曾是Cedars-Sinai Medical Center的Louis Warschaw前列腺癌中心的主任，也是the Warschaw，Robertson，Law Family前列腺癌第一任主席。Holden博士自2008年以来一直担任TelorMedix SA的董事会成员，并于1999年至2014年担任Acurian，Inc.的董事会成员。此外，他曾是洛杉矶Tower Urology的创始合伙人。Holden博士在威斯康星大学麦迪逊分校（University of Wisconsin-Madison）获得学士学位，并完成医学学位，在威尔·康奈尔医学院（Weill Cornell Medical College）和纽约医院-康奈尔大学医学院（New York Hospital-Cornell University Medical College）接受外科培训。他在埃默里大学医学院（Emory University School of Medicine）完成泌尿外科住院医师学位，并在Memorial Sloan-Kettering癌症中心获得泌尿外科和发育遗传学研究金。他还获得了the American Cancer Society的临床奖学金。根据本次发行前生效的公司章程授予该股东的权利，Holden博士被我们的股东之一ProQuest Investments IV，L.P.任命为董事会成员。
Stuart Holden,has been the Chair of ProQuest Investments' Scientific Advisory Board since it was founded in 1998. Since May 2014, Dr. Holden has served as a member of the UCLA faculty as a Health Sciences Clinical Professor of Urology, Spielberg Family Chair in Urologic Oncology, in the Department of Urology at the UCLA David Geffen School of Medicine and Associate Director of the UCLA Institute of Urologic Oncology. Dr. Holden has worked in the field of prostate cancer for more than 36 years. Dr. Holden also serves as Medical Director of the Prostate Cancer Foundation since the foundation's inception in 1993. Dr. Holden was the director of the Louis Warschaw Prostate Cancer Center at Cedars-Sinai Medical Center and the first holder of the Warschaw, Robertson, Law Families Chair in Prostate Cancer. Dr. Holden has served as a member of the board of directors of Telormedix SA from 2008 to 2017 and served as a member of the board of directors of Acurian, Inc. from 1999 through 2014. Dr. Holden also served on the Board of the American College of Medical Informatics from 1999 through 2006 and is currently on the board of Clarus Therapeutics, Inc. In addition, he was a founding partner at Tower Urology in Los Angeles. Dr. Holden received a B.S. degree from the University of Wisconsin-Madison and completed his medical degree and received his surgical training at Weill Cornell Medical College and the New York Hospital-Cornell University Medical College. He completed his urology residency at Emory University School of Medicine and fellowships in urology and developmental genetics at Memorial Sloan-Kettering Cancer Center. He also was awarded a clinical fellowship from the American Cancer Society. - Stuart Holden自2015年12月起担任我们的董事。自ProQuest Investments’；Scientific Advisory Board于1998年成立以来，Holden博士一直担任其董事长。自2014年5月起，Holden博士担任UCLA教员，担任泌尿外科健康科学临床教授，Spielberg家族泌尿肿瘤学主席，在加州大学洛杉矶分校大卫·格芬医学院泌尿外科和加州大学洛杉矶分校泌尿肿瘤研究所副主任。Holden博士在前列腺癌领域工作了超过36年。自1993年前列腺癌基金会成立以来，Holden博士还担任该基金会的医学总监。Holden博士曾是Cedars-Sinai Medical Center的Louis Warschaw前列腺癌中心的主任，也是the Warschaw，Robertson，Law Family前列腺癌第一任主席。Holden博士自2008年以来一直担任TelorMedix SA的董事会成员，并于1999年至2014年担任Acurian，Inc.的董事会成员。此外，他曾是洛杉矶Tower Urology的创始合伙人。Holden博士在威斯康星大学麦迪逊分校（University of Wisconsin-Madison）获得学士学位，并完成医学学位，在威尔·康奈尔医学院（Weill Cornell Medical College）和纽约医院-康奈尔大学医学院（New York Hospital-Cornell University Medical College）接受外科培训。他在埃默里大学医学院（Emory University School of Medicine）完成泌尿外科住院医师学位，并在Memorial Sloan-Kettering癌症中心获得泌尿外科和发育遗传学研究金。他还获得了the American Cancer Society的临床奖学金。根据本次发行前生效的公司章程授予该股东的权利，Holden博士被我们的股东之一ProQuest Investments IV，L.P.任命为董事会成员。
- Stuart Holden,has been the Chair of ProQuest Investments' Scientific Advisory Board since it was founded in 1998. Since May 2014, Dr. Holden has served as a member of the UCLA faculty as a Health Sciences Clinical Professor of Urology, Spielberg Family Chair in Urologic Oncology, in the Department of Urology at the UCLA David Geffen School of Medicine and Associate Director of the UCLA Institute of Urologic Oncology. Dr. Holden has worked in the field of prostate cancer for more than 36 years. Dr. Holden also serves as Medical Director of the Prostate Cancer Foundation since the foundation's inception in 1993. Dr. Holden was the director of the Louis Warschaw Prostate Cancer Center at Cedars-Sinai Medical Center and the first holder of the Warschaw, Robertson, Law Families Chair in Prostate Cancer. Dr. Holden has served as a member of the board of directors of Telormedix SA from 2008 to 2017 and served as a member of the board of directors of Acurian, Inc. from 1999 through 2014. Dr. Holden also served on the Board of the American College of Medical Informatics from 1999 through 2006 and is currently on the board of Clarus Therapeutics, Inc. In addition, he was a founding partner at Tower Urology in Los Angeles. Dr. Holden received a B.S. degree from the University of Wisconsin-Madison and completed his medical degree and received his surgical training at Weill Cornell Medical College and the New York Hospital-Cornell University Medical College. He completed his urology residency at Emory University School of Medicine and fellowships in urology and developmental genetics at Memorial Sloan-Kettering Cancer Center. He also was awarded a clinical fellowship from the American Cancer Society.
- Elizabeth Barrett
-
Elizabeth Barrett，自2019年1月起担任乌龙制药有限公司董事和乌龙制药有限公司总裁兼首席执行官。在加入UroGen之前，Barrett女士自2018年2月起担任诺华肿瘤学首席执行官和诺华执行委员会成员。在加入诺华之前，巴雷特女士曾在辉瑞公司担任过各种领导职务，最近担任肿瘤学全球总裁，在此之前担任欧洲全球创新制药总裁、北美专业护理业务部总裁和美国肿瘤学区域总裁。在加入辉瑞之前，Barrett女士是Cephalon公司副总裁兼肿瘤业务部门总经理。Barrett女士在圣约瑟夫大学获得工商管理-市场营销硕士学位，在路易斯安那大学获得学士学位。Barrett女士目前还担任Sage Therapeutics公司和Allogene Therapeutics, Inc.的董事。
Elizabeth Barrett,Prior to joining UroGen, Ms. Barrett served as the Chief Executive Officer of Novartis Oncology and a member of the Novartis Executive Committee since February 2018. Prior to Novartis, Ms. Barrett served at Pfizer Inc. in various leadership capacities, most recently as the Global President of Oncology and, before that, as President of Global Innovative Pharma for Europe, President of the Specialty Care Business Unit for North America, and Regional President of United States Oncology. Prior to Pfizer, Ms. Barrett was Vice President and General Manager of the Oncology Business Unit at Cephalon Inc. Ms. Barrett received an M.B.A. degree in Business Administration-Marketing from Saint Joseph's University and a B.S. from the University of Louisiana. Ms. Barrett also currently serves on the boards of directors of Sage Therapeutics, Inc. (since 2019) and Allogene Therapeutics, Inc. (since 2021). - Elizabeth Barrett，自2019年1月起担任乌龙制药有限公司董事和乌龙制药有限公司总裁兼首席执行官。在加入UroGen之前，Barrett女士自2018年2月起担任诺华肿瘤学首席执行官和诺华执行委员会成员。在加入诺华之前，巴雷特女士曾在辉瑞公司担任过各种领导职务，最近担任肿瘤学全球总裁，在此之前担任欧洲全球创新制药总裁、北美专业护理业务部总裁和美国肿瘤学区域总裁。在加入辉瑞之前，Barrett女士是Cephalon公司副总裁兼肿瘤业务部门总经理。Barrett女士在圣约瑟夫大学获得工商管理-市场营销硕士学位，在路易斯安那大学获得学士学位。Barrett女士目前还担任Sage Therapeutics公司和Allogene Therapeutics, Inc.的董事。
- Elizabeth Barrett,Prior to joining UroGen, Ms. Barrett served as the Chief Executive Officer of Novartis Oncology and a member of the Novartis Executive Committee since February 2018. Prior to Novartis, Ms. Barrett served at Pfizer Inc. in various leadership capacities, most recently as the Global President of Oncology and, before that, as President of Global Innovative Pharma for Europe, President of the Specialty Care Business Unit for North America, and Regional President of United States Oncology. Prior to Pfizer, Ms. Barrett was Vice President and General Manager of the Oncology Business Unit at Cephalon Inc. Ms. Barrett received an M.B.A. degree in Business Administration-Marketing from Saint Joseph's University and a B.S. from the University of Louisiana. Ms. Barrett also currently serves on the boards of directors of Sage Therapeutics, Inc. (since 2019) and Allogene Therapeutics, Inc. (since 2021).
- Cynthia M. Butitta
-
Cynthia M. Butitta，自2017年10月起担任乌龙制药有限公司董事。Butitta女士于2014年1月至2016年5月担任Kite Pharma公司首席财务官，并于2014年3月至2017年9月担任首席运营官。2011年5月至2012年12月，她在专业制药公司Next Wave Pharmaceuticals Inc.担任高级副总裁兼首席财务官。在此之前，Butitta女士于2001年3月至2010年12月担任生物制药公司Telik制药的首席运营官，并于1998年8月至2010年12月担任该公司的首席财务官。Buttita女士还担任Telik，Inc.的首席会计官，直至2010年12月。自2018年3月起担任生物技术公司Autolus有限公司董事；自2020年8月起担任Olema肿瘤学董事；自2021年2月起担任Century Therapeutics董事。Butitta女士在威斯康星州麦迪逊的Edgewood学院获得了商业和会计荣誉学士学位，并在威斯康星大学麦迪逊分校获得了金融MBA学位。
Cynthia M. Butitta,served as Chief Financial Officer of Kite Pharma, Inc. from January 2014 to May 2016 and as its Chief Operating Officer from March 2014 to September 2017. From May 2011 to December 2012, she was Senior Vice President and Chief Financial Officer at NextWave Pharmaceuticals Inc., a specialty pharmaceutical company. Prior to that, Ms. Butitta served as Chief Operating Officer of Telik, Inc., a biopharmaceutical company, from March 2001 to December 2010 and as its Chief Financial Officer from August 1998 to December 2010. Ms. Butitta also served as Principal Accounting Officer of Telik, Inc. until December 2010. She has served as a Director of Autolus, Ltd., a biotechnology company, since March 2018; a board member of Olema Oncology since August 2020 and Century Therapeutics, Inc. since February 2021. Ms. Butitta received her B.S. degree with honors in Business and Accounting from Edgewood College in Madison, Wisconsin and her M.B.A. degree in Finance from the University of Wisconsin-Madison. - Cynthia M. Butitta，自2017年10月起担任乌龙制药有限公司董事。Butitta女士于2014年1月至2016年5月担任Kite Pharma公司首席财务官，并于2014年3月至2017年9月担任首席运营官。2011年5月至2012年12月，她在专业制药公司Next Wave Pharmaceuticals Inc.担任高级副总裁兼首席财务官。在此之前，Butitta女士于2001年3月至2010年12月担任生物制药公司Telik制药的首席运营官，并于1998年8月至2010年12月担任该公司的首席财务官。Buttita女士还担任Telik，Inc.的首席会计官，直至2010年12月。自2018年3月起担任生物技术公司Autolus有限公司董事；自2020年8月起担任Olema肿瘤学董事；自2021年2月起担任Century Therapeutics董事。Butitta女士在威斯康星州麦迪逊的Edgewood学院获得了商业和会计荣誉学士学位，并在威斯康星大学麦迪逊分校获得了金融MBA学位。
- Cynthia M. Butitta,served as Chief Financial Officer of Kite Pharma, Inc. from January 2014 to May 2016 and as its Chief Operating Officer from March 2014 to September 2017. From May 2011 to December 2012, she was Senior Vice President and Chief Financial Officer at NextWave Pharmaceuticals Inc., a specialty pharmaceutical company. Prior to that, Ms. Butitta served as Chief Operating Officer of Telik, Inc., a biopharmaceutical company, from March 2001 to December 2010 and as its Chief Financial Officer from August 1998 to December 2010. Ms. Butitta also served as Principal Accounting Officer of Telik, Inc. until December 2010. She has served as a Director of Autolus, Ltd., a biotechnology company, since March 2018; a board member of Olema Oncology since August 2020 and Century Therapeutics, Inc. since February 2021. Ms. Butitta received her B.S. degree with honors in Business and Accounting from Edgewood College in Madison, Wisconsin and her M.B.A. degree in Finance from the University of Wisconsin-Madison.
- James A. Robinson, Jr
-
James A. Robinson，Jr.自2023年7月起担任乌龙制药有限公司董事。2020年3月至2023年6月担任Urovant Sciences首席执行官。在加入Urovant Sciences之前，Robinson先生于2019年4月至2020年3月担任Paragon Biosciences的总裁兼首席运营官，负责监督Paragon的运营，并担任Paragon投资组合公司Qlarity Imaging的首席执行官。在加入Paragon之前，他于2018年3月至2019年4月担任阿尔凯默斯公司总裁兼首席运营官，负责全球商业、新产品规划、企业规划、制造、质量、人力资源和业务发展职能。他还曾在Astellas U.S.和Schering-Plough制药公司担任重要职务，专注于商业运营和销售。罗宾逊先生于2019年至2023年6月担任Urovant Sciences董事会成员。他曾于2021-2022年担任AGTC董事会成员，后于2022年12月被出售给Syncona LTD。从2019年到2021年3月，鲁滨逊先生担任Neos治疗董事会成员。他还担任美国药物研究和制造商（PhRMA）的董事会成员，并担任PhRMA州委员会主席。他是MATTER的创始成员。鲁滨逊先生是芝加哥商业俱乐部的成员和青年总统组织芝加哥分会的成员。罗宾逊先生在生物制药行业拥有30多年的经验，从创立到取得商业成功，他在建立和领导组织方面表现出色。Robinson先生获得了德保罗大学的理学学士学位。
James A. Robinson, Jr,currently serves as the President, Chief Executive Officer and member of the board directors of A2 Biotherapeutics, Inc. Prior to this role, he served as the Chief Executive Officer of Urovant Sciences, Inc. from March 2020 through June 2023 and has served as a member of Urovant's board of directors from March 2019 through June 2023. Prior to Urovant Sciences, Mr. Robinson held the position of President and Chief Operating Officer at Paragon Biosciences, where he oversaw Paragon's operations from April 2019 to March 2020. Previously, Mr. Robinson served as the President and Chief Operating Officer of Alkermes, where he was responsible for global commercial, new product planning, corporate planning, manufacturing, quality, human resources and business development functions. Prior to Alkermes, Mr. Robinson spent over twelve years at Astellas U.S., most recently as President, Americas Operations, where his responsibilities included all aspects of operations for North and South America. Prior to that, he was President of Astellas Pharma US, where he was responsible for leading the U.S. commercial organization. Prior to Astellas, Mr. Robinson spent thirteen years at Schering-Plough Pharmaceuticals, where his last role was Vice President, Hepatitis Sales and Managed Care. Mr. Robinson currently serves as an advisor to BridgeBio Pharma, Inc. and on the board of directors of Eledon Pharmaceuticals, Inc., a public biotechnology company, and Petauri Health, a private healthcare service company. Previously, Mr. Robinson served on the board of directors of Neos Therapeutics, Inc. prior to its acquisition by Aytu Biopharma, Inc. as well as the board of directors of Applied Genetic Technologies Corporation until its acquisition by Syncona LTD in November 2022. He also previously served on the board of directors of the Pharmaceutical Research and Manufacturers of America ("PhRMA") and served as Chairman of PhRMA's State Committee. He is a founding member of MATTER. Mr. Robinson received a Bachelor of Science degree from DePaul University. - James A. Robinson，Jr.自2023年7月起担任乌龙制药有限公司董事。2020年3月至2023年6月担任Urovant Sciences首席执行官。在加入Urovant Sciences之前，Robinson先生于2019年4月至2020年3月担任Paragon Biosciences的总裁兼首席运营官，负责监督Paragon的运营，并担任Paragon投资组合公司Qlarity Imaging的首席执行官。在加入Paragon之前，他于2018年3月至2019年4月担任阿尔凯默斯公司总裁兼首席运营官，负责全球商业、新产品规划、企业规划、制造、质量、人力资源和业务发展职能。他还曾在Astellas U.S.和Schering-Plough制药公司担任重要职务，专注于商业运营和销售。罗宾逊先生于2019年至2023年6月担任Urovant Sciences董事会成员。他曾于2021-2022年担任AGTC董事会成员，后于2022年12月被出售给Syncona LTD。从2019年到2021年3月，鲁滨逊先生担任Neos治疗董事会成员。他还担任美国药物研究和制造商（PhRMA）的董事会成员，并担任PhRMA州委员会主席。他是MATTER的创始成员。鲁滨逊先生是芝加哥商业俱乐部的成员和青年总统组织芝加哥分会的成员。罗宾逊先生在生物制药行业拥有30多年的经验，从创立到取得商业成功，他在建立和领导组织方面表现出色。Robinson先生获得了德保罗大学的理学学士学位。
- James A. Robinson, Jr,currently serves as the President, Chief Executive Officer and member of the board directors of A2 Biotherapeutics, Inc. Prior to this role, he served as the Chief Executive Officer of Urovant Sciences, Inc. from March 2020 through June 2023 and has served as a member of Urovant's board of directors from March 2019 through June 2023. Prior to Urovant Sciences, Mr. Robinson held the position of President and Chief Operating Officer at Paragon Biosciences, where he oversaw Paragon's operations from April 2019 to March 2020. Previously, Mr. Robinson served as the President and Chief Operating Officer of Alkermes, where he was responsible for global commercial, new product planning, corporate planning, manufacturing, quality, human resources and business development functions. Prior to Alkermes, Mr. Robinson spent over twelve years at Astellas U.S., most recently as President, Americas Operations, where his responsibilities included all aspects of operations for North and South America. Prior to that, he was President of Astellas Pharma US, where he was responsible for leading the U.S. commercial organization. Prior to Astellas, Mr. Robinson spent thirteen years at Schering-Plough Pharmaceuticals, where his last role was Vice President, Hepatitis Sales and Managed Care. Mr. Robinson currently serves as an advisor to BridgeBio Pharma, Inc. and on the board of directors of Eledon Pharmaceuticals, Inc., a public biotechnology company, and Petauri Health, a private healthcare service company. Previously, Mr. Robinson served on the board of directors of Neos Therapeutics, Inc. prior to its acquisition by Aytu Biopharma, Inc. as well as the board of directors of Applied Genetic Technologies Corporation until its acquisition by Syncona LTD in November 2022. He also previously served on the board of directors of the Pharmaceutical Research and Manufacturers of America ("PhRMA") and served as Chairman of PhRMA's State Committee. He is a founding member of MATTER. Mr. Robinson received a Bachelor of Science degree from DePaul University.
- Leana S. Wen
-
Leana S. Wen，自2022年8月起担任乌龙制药有限公司董事。温博士是一名急诊医师，自2019年9月起担任乔治·华盛顿大学公共卫生学院卫生政策与管理教授。自2020年6月以来，她一直是《华盛顿邮报》的特约专栏作家，撰写有关卫生政策和公共卫生的文章，自2020年8月以来，她作为一名医学分析师，担任CNN的直播评论员。2015年1月至2018年10月，她担任巴尔的摩市卫生专员，领导全美历史最悠久、持续运作的卫生部门抗击阿片类药物疫情，改善母婴健康。从2013年到2015年，温博士在乔治华盛顿大学急诊医学系担任以病人为中心的护理研究主任，并著有一本关于病人倡导的广受好评的书。她目前是两党政策中心、巴尔的摩社区基金会和美中关系全国委员会的董事，并担任行为健康小组的顾问委员会主席。她还担任过世界卫生组织全球卫生研究员、中国医学委员会顾问、布鲁金斯学会非常驻高级研究员。从2018年到2019年，温博士还担任计划生育协会会长。她是十多个非营利委员会的成员，包括巴尔的摩行为健康系统的主席。自2021年3月起，温博士还担任Glaukos Corporation董事会成员，并担任其审计委员会成员。温博士的工作得到了众多专业机构的认可，包括《现代医疗》杂志的前50名医师和高管，以及美国对外关系委员会的成员。2019年，她被《时代》杂志评为100位最具影响力人物，2022年，她被评为Modern Healthcare的100位最具影响力人物之一。她拥有加州州立大学洛杉矶分校的学士学位、华盛顿大学医学院的医学博士学位和牛津大学的两个理学硕士学位，她曾是牛津大学的罗德学者。她在布莱根妇女医院和麻省总医院完成了住院医师培训，并在哈佛医学院担任临床研究员。
Leana S. Wen,is an emergency physician and has served as a faculty member at the George Washington University since September 2019. She has been a contributing columnist for The Washington Post since June 2020, writing on health policy and public health, and a health and medical expert for CNN since August 2020. From January 2015 to October 2018, she was the health commissioner for the city of Baltimore, where she led the nation's oldest continuously operating health department to combat the opioid epidemic and improve maternal and child health. From 2013 to 2015, Dr. Wen served as director of patient-centered care research in the department of emergency medicine at George Washington University, and authored a critically-acclaimed book on patient advocacy. She is currently on the board of the Bipartisan Policy Center and the Baltimore Community Foundation, and chairs the advisory board of the Behavioral Health Group. She has also been a global health fellow at the World Health Organization, a consultant with the China Medical Board, and a nonresident senior fellow at the Brookings Institution. Dr. Wen also served as the President of Planned Parenthood from 2018 through 2019. She has been a member of more than ten nonprofit boards, including serving as the chair of Behavioral Health System Baltimore. Dr. Wen has also served on the board of directors of Glaukos Corporation since March 2021 and also serves on its audit committee. Dr. Wen's work has been recognized by numerous professional organizations, including as one of Modern Healthcare's Top 50 Physician-Executives and a member of the Council on Foreign Relationships. In 2019, she was named one of TIME magazine's 100 Most Influential People and in 2022 as one of Modern Healthcare's 100 Most Influential People in Healthcare. She holds a B.S. from California State University, Los Angeles, an M.D. from Washington University School of Medicine and two M.Sc.s from the University of Oxford, where she was a Rhodes Scholar. She completed her residency training at Brigham & Women's Hospital and Massachusetts General Hospital, where she was a clinical fellow at Harvard Medical School. - Leana S. Wen，自2022年8月起担任乌龙制药有限公司董事。温博士是一名急诊医师，自2019年9月起担任乔治·华盛顿大学公共卫生学院卫生政策与管理教授。自2020年6月以来，她一直是《华盛顿邮报》的特约专栏作家，撰写有关卫生政策和公共卫生的文章，自2020年8月以来，她作为一名医学分析师，担任CNN的直播评论员。2015年1月至2018年10月，她担任巴尔的摩市卫生专员，领导全美历史最悠久、持续运作的卫生部门抗击阿片类药物疫情，改善母婴健康。从2013年到2015年，温博士在乔治华盛顿大学急诊医学系担任以病人为中心的护理研究主任，并著有一本关于病人倡导的广受好评的书。她目前是两党政策中心、巴尔的摩社区基金会和美中关系全国委员会的董事，并担任行为健康小组的顾问委员会主席。她还担任过世界卫生组织全球卫生研究员、中国医学委员会顾问、布鲁金斯学会非常驻高级研究员。从2018年到2019年，温博士还担任计划生育协会会长。她是十多个非营利委员会的成员，包括巴尔的摩行为健康系统的主席。自2021年3月起，温博士还担任Glaukos Corporation董事会成员，并担任其审计委员会成员。温博士的工作得到了众多专业机构的认可，包括《现代医疗》杂志的前50名医师和高管，以及美国对外关系委员会的成员。2019年，她被《时代》杂志评为100位最具影响力人物，2022年，她被评为Modern Healthcare的100位最具影响力人物之一。她拥有加州州立大学洛杉矶分校的学士学位、华盛顿大学医学院的医学博士学位和牛津大学的两个理学硕士学位，她曾是牛津大学的罗德学者。她在布莱根妇女医院和麻省总医院完成了住院医师培训，并在哈佛医学院担任临床研究员。
- Leana S. Wen,is an emergency physician and has served as a faculty member at the George Washington University since September 2019. She has been a contributing columnist for The Washington Post since June 2020, writing on health policy and public health, and a health and medical expert for CNN since August 2020. From January 2015 to October 2018, she was the health commissioner for the city of Baltimore, where she led the nation's oldest continuously operating health department to combat the opioid epidemic and improve maternal and child health. From 2013 to 2015, Dr. Wen served as director of patient-centered care research in the department of emergency medicine at George Washington University, and authored a critically-acclaimed book on patient advocacy. She is currently on the board of the Bipartisan Policy Center and the Baltimore Community Foundation, and chairs the advisory board of the Behavioral Health Group. She has also been a global health fellow at the World Health Organization, a consultant with the China Medical Board, and a nonresident senior fellow at the Brookings Institution. Dr. Wen also served as the President of Planned Parenthood from 2018 through 2019. She has been a member of more than ten nonprofit boards, including serving as the chair of Behavioral Health System Baltimore. Dr. Wen has also served on the board of directors of Glaukos Corporation since March 2021 and also serves on its audit committee. Dr. Wen's work has been recognized by numerous professional organizations, including as one of Modern Healthcare's Top 50 Physician-Executives and a member of the Council on Foreign Relationships. In 2019, she was named one of TIME magazine's 100 Most Influential People and in 2022 as one of Modern Healthcare's 100 Most Influential People in Healthcare. She holds a B.S. from California State University, Los Angeles, an M.D. from Washington University School of Medicine and two M.Sc.s from the University of Oxford, where she was a Rhodes Scholar. She completed her residency training at Brigham & Women's Hospital and Massachusetts General Hospital, where she was a clinical fellow at Harvard Medical School.
- Daniel Wildman
-
Daniel Wildman，自2022年11月起担任乌龙制药有限公司董事。他是Progenerative Medical，Inc.董事会主席，该公司是一家商业前公司，将临床证明的减压技术转化为骨科手术的医疗治疗。他还担任多家医疗设备/制药公司的战略顾问。从2000年5月到2017年9月，怀德曼先生在强生工作，最近领导数字手术战略计划，负责为公司制定机器人手术的综合战略。这一战略直接导致了2019年对Auris Health，Inc.的收购。在加入数字外科之前，Wildman先生曾于2015年8月至2017年9月担任Depuy Synthes Spine的全球总裁。在这个职位上，他全面负责全球第二大脊柱外科业务（1.8B美元）。在此期间，为该公司制定并实施了一项综合转型计划。从2003年至2015年，Wildman先生担任Ethicon Biosurgery的全球总裁，Ethicon Biosurgery是Ethicon，Inc.的一个部门，在那里他领导了这家全球企业，致力于通过生物材料、生物和组合产品的开发和商业化，为外科医生提供创新和挽救生命的解决方案，这些产品改变了术中止血的护理标准。在担任这一职务期间，怀尔德曼先生通过收购、资产剥离和内部能力开发的组合，将公司从高级伤口护理过渡到生物外科，所有这些都专注于有意义的创新的开发和商业化。在加入强生之前，Wildman先生在波士顿科学国际有限公司工作了10年，担任过各种销售、市场营销、运营和战略规划方面的职务。怀德曼先生是一位成就卓著的全球领袖。在他的整个职业生涯中，他因其战略眼光、激励性领导、创新技术、执行能力和对人的发展的承诺而赢得了良好的声誉。Wildman先生在纽约圣劳伦斯大学获得经济学学士学位。
Daniel Wildman,has served as Urogen Pharma Ltd. director since November 2022. Mr. is Chairman of the Board of Progenerative Medical, Inc., a pre-commercial company translating clinically proven reduced pressure technology into medical treatments for orthopedic surgeries. He also serves as a Strategic Adviser for several medical device/pharmaceutical companies. From May 2000 to September 2017, Mr. Wildman worked at Johnson & Johnson, most recently leading the Digital Surgery Strategy initiative where he was tasked with developing an integrated strategy for robotic surgery for the company. This strategy directly led to the 2019 acquisition of Auris Health, Inc. Prior to Digital Surgery, Mr. Wildman served as Worldwide President of Depuy Synthes Spine from August of 2015 to September of 2017. In this role, he had overall responsibility for the second-largest spine surgery business in the world ($1.8B). During this period developed and implemented an integrated turn-around plan for the company. From 2003-2015, Mr. Wildman served as Worldwide President of Ethicon Biosurgery, a division of Ethicon, Inc., where he led this global business dedicated to delivering innovative and life-saving solutions to surgeons via development and commercialization of biomaterial, biologic and combination products that changed the standard of care for intraoperative hemostasis. In this role, Mr. Wildman transitioned the company from Advanced Wound Care to Biosurgery through a combination of acquisitions, divestitures, and internal capability development, all focused on development and commercialization of meaningful innovations. Prior to Johnson & Johnson, Mr. Wildman spent 10 years with Boston Scientific Corporation in a variety of sales, marketing, operations and strategic planning roles of increasing responsibility. Mr. Wildman is an accomplished global leader. Throughout his career, he has earned a solid reputation for his strategic vision, motivational leadership, innovative technologies, ability to execute and his commitment to people development. Mr. Wildman received a Bachelor of Arts degree in Economics from St. Lawrence University in New York. - Daniel Wildman，自2022年11月起担任乌龙制药有限公司董事。他是Progenerative Medical，Inc.董事会主席，该公司是一家商业前公司，将临床证明的减压技术转化为骨科手术的医疗治疗。他还担任多家医疗设备/制药公司的战略顾问。从2000年5月到2017年9月，怀德曼先生在强生工作，最近领导数字手术战略计划，负责为公司制定机器人手术的综合战略。这一战略直接导致了2019年对Auris Health，Inc.的收购。在加入数字外科之前，Wildman先生曾于2015年8月至2017年9月担任Depuy Synthes Spine的全球总裁。在这个职位上，他全面负责全球第二大脊柱外科业务（1.8B美元）。在此期间，为该公司制定并实施了一项综合转型计划。从2003年至2015年，Wildman先生担任Ethicon Biosurgery的全球总裁，Ethicon Biosurgery是Ethicon，Inc.的一个部门，在那里他领导了这家全球企业，致力于通过生物材料、生物和组合产品的开发和商业化，为外科医生提供创新和挽救生命的解决方案，这些产品改变了术中止血的护理标准。在担任这一职务期间，怀尔德曼先生通过收购、资产剥离和内部能力开发的组合，将公司从高级伤口护理过渡到生物外科，所有这些都专注于有意义的创新的开发和商业化。在加入强生之前，Wildman先生在波士顿科学国际有限公司工作了10年，担任过各种销售、市场营销、运营和战略规划方面的职务。怀德曼先生是一位成就卓著的全球领袖。在他的整个职业生涯中，他因其战略眼光、激励性领导、创新技术、执行能力和对人的发展的承诺而赢得了良好的声誉。Wildman先生在纽约圣劳伦斯大学获得经济学学士学位。
- Daniel Wildman,has served as Urogen Pharma Ltd. director since November 2022. Mr. is Chairman of the Board of Progenerative Medical, Inc., a pre-commercial company translating clinically proven reduced pressure technology into medical treatments for orthopedic surgeries. He also serves as a Strategic Adviser for several medical device/pharmaceutical companies. From May 2000 to September 2017, Mr. Wildman worked at Johnson & Johnson, most recently leading the Digital Surgery Strategy initiative where he was tasked with developing an integrated strategy for robotic surgery for the company. This strategy directly led to the 2019 acquisition of Auris Health, Inc. Prior to Digital Surgery, Mr. Wildman served as Worldwide President of Depuy Synthes Spine from August of 2015 to September of 2017. In this role, he had overall responsibility for the second-largest spine surgery business in the world ($1.8B). During this period developed and implemented an integrated turn-around plan for the company. From 2003-2015, Mr. Wildman served as Worldwide President of Ethicon Biosurgery, a division of Ethicon, Inc., where he led this global business dedicated to delivering innovative and life-saving solutions to surgeons via development and commercialization of biomaterial, biologic and combination products that changed the standard of care for intraoperative hemostasis. In this role, Mr. Wildman transitioned the company from Advanced Wound Care to Biosurgery through a combination of acquisitions, divestitures, and internal capability development, all focused on development and commercialization of meaningful innovations. Prior to Johnson & Johnson, Mr. Wildman spent 10 years with Boston Scientific Corporation in a variety of sales, marketing, operations and strategic planning roles of increasing responsibility. Mr. Wildman is an accomplished global leader. Throughout his career, he has earned a solid reputation for his strategic vision, motivational leadership, innovative technologies, ability to execute and his commitment to people development. Mr. Wildman received a Bachelor of Arts degree in Economics from St. Lawrence University in New York.
- Daniel G. Wildman
-
Daniel G. Wildman是Progenerative Medical，Inc.的董事会主席，该公司是一家商业前公司，将临床证明的减压技术转化为骨科手术的医疗治疗。他还在Nyxoah S.A.、Progenerative Medical，Inc.和PanTher Therapeutics，Inc.的董事会任职。在强生，Wildman先生领导了数字手术战略计划，负责为公司制定机器人手术的综合战略。这一战略直接导致了2019年对Auris Health，Inc.的收购。在数字手术之前，Wildman先生领导了Depuy Synthes Spine。在这个职位上，他全面负责全球第二大脊柱手术业务（$ 1.8B）。他曾于2015年8月至2017年9月担任这一职务，并在此期间制定并实施了公司的综合转型计划。此前，Wildman先生曾担任Ethicon Biosurgery的全球总裁，Ethicon Biosurgery是Ethicon，Inc.的一个部门。从2003年到2015年，他领导了这一全球业务，致力于通过生物材料、生物制剂和组合产品的开发和商业化，为外科医生提供创新和挽救生命的解决方案，这些产品改变了术中止血的护理标准。在担任这一职务时，Wildman先生通过收购、资产剥离和内部能力发展相结合的方式，将公司从高级伤口护理过渡到生物外科，所有这些都专注于有意义的创新的开发和商业化。Ethicon的生物外科业务仍然是强生投资组合中增长最快的公司之一。在加入强生之前，Wildman先生曾在波士顿科学国际有限公司工作了10年，担任过越来越多的销售、市场营销、运营和战略规划职务。怀尔德曼先生是一位成就卓著的全球领导者。在他的整个职业生涯中，他凭借战略眼光、激励性领导、创新技术、执行能力和对人的发展的承诺赢得了稳固的声誉。Wildman先生在纽约圣劳伦斯大学获得经济学文学学士学位。
Daniel G. Wildman,is Chairman of the Board of Progenerative Medical, Inc., a pre-commercial company translating clinically proven reduced pressure technology into medical treatments for orthopedic surgeries. He also serves on the board of directors of Nyxoah S.A., Progenerative Medical, Inc. and PanTher Therapeutics, Inc. At Johnson & Johnson, Mr. Wildman led the Digital Surgery Strategy initiative, where he was tasked with developing an integrated strategy for robotic surgery for the company. This strategy directly led to the 2019 acquisition of Auris Health, Inc. Prior to Digital Surgery, Mr. Wildman led Depuy Synthes Spine. In this role, he had overall responsibility for the second-largest spine surgery business in the world ($1.8B). He served in this capacity from August of 2015 to September of 2017, and during this period developed and implemented an integrated turn-around plan for the company. Previously, Mr. Wildman served as Worldwide President of Ethicon Biosurgery, a division of Ethicon, Inc. From 2003 to 2015 he led this global business dedicated to delivering innovative and life-saving solutions to surgeons via development and commercialization of biomaterial, biologic and combination products that changed the standard of care for intraoperative hemostasis. In this role, Mr. Wildman transitioned the company from Advanced Wound Care to Biosurgery through a combination of acquisitions, divestitures, and internal capability development, all focused on development and commercialization of meaningful innovations. The Biosurgery business at Ethicon continues to be one of the fastest growing companies in Johnson & Johnson's portfolio. Prior to Johnson & Johnson, Mr. Wildman spent 10 years with Boston Scientific Corporation in a variety of sales, marketing, operations and strategic planning roles of increasing responsibility. Mr. Wildman is an accomplished global leader. Throughout his career, he has earned a solid reputation for his strategic vision, motivational leadership, innovative technologies, ability to execute and his commitment to people development. Mr. Wildman received a Bachelor of Arts degree in Economics from St. Lawrence University in New York. - Daniel G. Wildman是Progenerative Medical，Inc.的董事会主席，该公司是一家商业前公司，将临床证明的减压技术转化为骨科手术的医疗治疗。他还在Nyxoah S.A.、Progenerative Medical，Inc.和PanTher Therapeutics，Inc.的董事会任职。在强生，Wildman先生领导了数字手术战略计划，负责为公司制定机器人手术的综合战略。这一战略直接导致了2019年对Auris Health，Inc.的收购。在数字手术之前，Wildman先生领导了Depuy Synthes Spine。在这个职位上，他全面负责全球第二大脊柱手术业务（$ 1.8B）。他曾于2015年8月至2017年9月担任这一职务，并在此期间制定并实施了公司的综合转型计划。此前，Wildman先生曾担任Ethicon Biosurgery的全球总裁，Ethicon Biosurgery是Ethicon，Inc.的一个部门。从2003年到2015年，他领导了这一全球业务，致力于通过生物材料、生物制剂和组合产品的开发和商业化，为外科医生提供创新和挽救生命的解决方案，这些产品改变了术中止血的护理标准。在担任这一职务时，Wildman先生通过收购、资产剥离和内部能力发展相结合的方式，将公司从高级伤口护理过渡到生物外科，所有这些都专注于有意义的创新的开发和商业化。Ethicon的生物外科业务仍然是强生投资组合中增长最快的公司之一。在加入强生之前，Wildman先生曾在波士顿科学国际有限公司工作了10年，担任过越来越多的销售、市场营销、运营和战略规划职务。怀尔德曼先生是一位成就卓著的全球领导者。在他的整个职业生涯中，他凭借战略眼光、激励性领导、创新技术、执行能力和对人的发展的承诺赢得了稳固的声誉。Wildman先生在纽约圣劳伦斯大学获得经济学文学学士学位。
- Daniel G. Wildman,is Chairman of the Board of Progenerative Medical, Inc., a pre-commercial company translating clinically proven reduced pressure technology into medical treatments for orthopedic surgeries. He also serves on the board of directors of Nyxoah S.A., Progenerative Medical, Inc. and PanTher Therapeutics, Inc. At Johnson & Johnson, Mr. Wildman led the Digital Surgery Strategy initiative, where he was tasked with developing an integrated strategy for robotic surgery for the company. This strategy directly led to the 2019 acquisition of Auris Health, Inc. Prior to Digital Surgery, Mr. Wildman led Depuy Synthes Spine. In this role, he had overall responsibility for the second-largest spine surgery business in the world ($1.8B). He served in this capacity from August of 2015 to September of 2017, and during this period developed and implemented an integrated turn-around plan for the company. Previously, Mr. Wildman served as Worldwide President of Ethicon Biosurgery, a division of Ethicon, Inc. From 2003 to 2015 he led this global business dedicated to delivering innovative and life-saving solutions to surgeons via development and commercialization of biomaterial, biologic and combination products that changed the standard of care for intraoperative hemostasis. In this role, Mr. Wildman transitioned the company from Advanced Wound Care to Biosurgery through a combination of acquisitions, divestitures, and internal capability development, all focused on development and commercialization of meaningful innovations. The Biosurgery business at Ethicon continues to be one of the fastest growing companies in Johnson & Johnson's portfolio. Prior to Johnson & Johnson, Mr. Wildman spent 10 years with Boston Scientific Corporation in a variety of sales, marketing, operations and strategic planning roles of increasing responsibility. Mr. Wildman is an accomplished global leader. Throughout his career, he has earned a solid reputation for his strategic vision, motivational leadership, innovative technologies, ability to execute and his commitment to people development. Mr. Wildman received a Bachelor of Arts degree in Economics from St. Lawrence University in New York.
- Arie Belldegrun
-
Arie Belldegrun，他是Allogene Therapeutics（公共生物制药公司）的联合创始人，并自2017年11月起担任其董事会执行主席。2014年3月至2017年10月，Belldegrun博士担任Kite Pharma， Inc.的总裁兼首席执行官，2009年6月至2017年10月担任其董事会成员。他也是Gingko Bioworks的董事（从2021年9月到2024年11月）。Belldegrun博士目前担任Bellco Capital LLC的董事长（自2004年以来）；Two River董事长兼合伙人（2009年6月起）；Breakthrough Properties LLC和Breakthrough Services， L.L.C.联合主席（自2019年4月起）；Kronos Bio董事长（自2017年11月起）；Symbiotic Capital联席主席（自2023年6月起）；ByHeart, Inc.的董事（自2019年10月起）。Belldegrun博士也是Vida Ventures， LLC的高级常务董事（自2017年11月以来）。Belldegrun博士是一名研究教授，拥有泌尿肿瘤学的Roy和Carol Doumani主席，也是加州大学洛杉矶分校David Geffen医学院泌尿肿瘤学研究所的创始人和主任。加入UCLA之前，Belldegrun博士在National Cancer Institute/NIH担任Steven a . Rosenberg博士的外科肿瘤学和免疫疗法研究员。他在耶路撒冷的Hebrew大学哈达萨医学院完成了医学博士学位，在Weizmann Institute of Science完成了免疫学研究生学习，并在哈佛医学院完成了泌尿外科住院医师。他撰写了几本肿瘤学书籍，并撰写了500多篇与泌尿系统癌症、免疫治疗、基因治疗和癌症疫苗相关的科学和医学论文。他获得了美国泌尿外科委员会和美国泌尿生殖外科医生协会的认证。
Arie Belldegrun,is a co-founder of Allogene Therapeutics, a public biopharmaceutical company, and has served as Executive Chairman of its board of directors since November 2017. From March 2014 until October 2017, Dr. Belldegrun served as the President and Chief Executive Officer of Kite Pharma, Inc. and as a member of its board of directors from June 2009 until October 2017. He was also a Director of Gingko Bioworks (from September 2021 to November 2024). Dr. Belldegrun currently serves as Chairman of Bellco Capital LLC (since 2004); Chairman and Partner of Two River (since June 2009); Co-chairman of Breakthrough Properties LLC and Breakthrough Services, L.L.C. (since April 2019); Chairman of Kronos Bio (since November 2017); Co-chairman of Symbiotic Capital (since June 2023); and Director of ByHeart, Inc. (since October 2019). Dr. Belldegrun is also Senior Managing Director of Vida Ventures, LLC (since November 2017). Dr. Belldegrun is a Research Professor, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Founder and Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA, Dr. Belldegrun was at the National Cancer Institute/NIH as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. He completed his M.D. at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in Immunology at the Weizmann Institute of Science, and his residency in urologic surgery at Harvard Medical School. He has authored several books on oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy and cancer vaccines. He is certified by the American Board of Urology and the American Association of Genitourinary Surgeons. - Arie Belldegrun，他是Allogene Therapeutics（公共生物制药公司）的联合创始人，并自2017年11月起担任其董事会执行主席。2014年3月至2017年10月，Belldegrun博士担任Kite Pharma， Inc.的总裁兼首席执行官，2009年6月至2017年10月担任其董事会成员。他也是Gingko Bioworks的董事（从2021年9月到2024年11月）。Belldegrun博士目前担任Bellco Capital LLC的董事长（自2004年以来）；Two River董事长兼合伙人（2009年6月起）；Breakthrough Properties LLC和Breakthrough Services， L.L.C.联合主席（自2019年4月起）；Kronos Bio董事长（自2017年11月起）；Symbiotic Capital联席主席（自2023年6月起）；ByHeart, Inc.的董事（自2019年10月起）。Belldegrun博士也是Vida Ventures， LLC的高级常务董事（自2017年11月以来）。Belldegrun博士是一名研究教授，拥有泌尿肿瘤学的Roy和Carol Doumani主席，也是加州大学洛杉矶分校David Geffen医学院泌尿肿瘤学研究所的创始人和主任。加入UCLA之前，Belldegrun博士在National Cancer Institute/NIH担任Steven a . Rosenberg博士的外科肿瘤学和免疫疗法研究员。他在耶路撒冷的Hebrew大学哈达萨医学院完成了医学博士学位，在Weizmann Institute of Science完成了免疫学研究生学习，并在哈佛医学院完成了泌尿外科住院医师。他撰写了几本肿瘤学书籍，并撰写了500多篇与泌尿系统癌症、免疫治疗、基因治疗和癌症疫苗相关的科学和医学论文。他获得了美国泌尿外科委员会和美国泌尿生殖外科医生协会的认证。
- Arie Belldegrun,is a co-founder of Allogene Therapeutics, a public biopharmaceutical company, and has served as Executive Chairman of its board of directors since November 2017. From March 2014 until October 2017, Dr. Belldegrun served as the President and Chief Executive Officer of Kite Pharma, Inc. and as a member of its board of directors from June 2009 until October 2017. He was also a Director of Gingko Bioworks (from September 2021 to November 2024). Dr. Belldegrun currently serves as Chairman of Bellco Capital LLC (since 2004); Chairman and Partner of Two River (since June 2009); Co-chairman of Breakthrough Properties LLC and Breakthrough Services, L.L.C. (since April 2019); Chairman of Kronos Bio (since November 2017); Co-chairman of Symbiotic Capital (since June 2023); and Director of ByHeart, Inc. (since October 2019). Dr. Belldegrun is also Senior Managing Director of Vida Ventures, LLC (since November 2017). Dr. Belldegrun is a Research Professor, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Founder and Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA, Dr. Belldegrun was at the National Cancer Institute/NIH as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. He completed his M.D. at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in Immunology at the Weizmann Institute of Science, and his residency in urologic surgery at Harvard Medical School. He has authored several books on oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy and cancer vaccines. He is certified by the American Board of Urology and the American Association of Genitourinary Surgeons.
高管简历
中英对照 | 中文 | 英文- Chris Degnan
Chris Degnan自2018年3月起担任我们的首席财务官。在加入我们公司之前，德南从2014年11月开始在仿制药和专业品牌制药公司Endo International plc（McKinsey）担任越来越重要的职务，最近担任该公司财务Vice President，2016年12月至2018年3月，企业FP&A和国际制药部门首席财务官。在此之前，他是Endo&8217；S.U.Brand Pharmaceuticals分部的财务、首席财务官Vice President。在加入Endo之前，Degnan先生从2004年开始在AstraZeneca PLC（一家全球生物制药公司）担任越来越重要的职务，最近从2013年7月到2014年11月担任美国商业金融高级财务总监。他是宾夕法尼亚州的一名注册会计师，自愿不活跃状态。Degnan先生拥有圣母大学（University of Notre Dame）会计学B.S.学位。
Chris Degnan,Prior to joining UroGen, Mr. Degnan served as the Chief Financial Officer of Galera Therapeutics, Inc., a public, late-stage biopharmaceutical company focused on oncology, from October 2019 to August 2024. Prior to Galera, Mr. Degnan served as the Chief Financial Officer of Verrica Pharmaceuticals Inc., a public, biotechnology company focused on medical dermatology, from March 2018 to October 2019. Prior to Verrica, Mr. Degnan held roles of increasing responsibility at Endo International plc, a generics and specialty branded pharmaceutical company, beginning in November 2014. At Endo, Mr. Degnan most recently served as the Vice President of Finance, Corporate FP&A and International Pharmaceuticals Segment Chief Financial Officer from December 2016 to March 2018. Prior to that, he served as the Vice President of Finance, Chief Financial Officer for Endo's U.S. Branded Pharmaceuticals segment from March 2016 to December 2016, and as the Senior Finance Director, U.S. Branded Pharmaceuticals from November 2014 to March 2016. Prior to joining Endo, Mr. Degnan held roles of increasing responsibility at AstraZeneca plc, a global biopharmaceutical company, beginning in 2004. At AstraZeneca, Mr. Degnan most recently served as Senior Finance Director, U.S. Commercial Finance from July 2013 to November 2014. Mr. Degnan is a Certified Public Accountant in the State of Pennsylvania (voluntary inactive status) and holds a B.B.A. degree in Accountancy from the University of Notre Dame.- Chris Degnan自2018年3月起担任我们的首席财务官。在加入我们公司之前，德南从2014年11月开始在仿制药和专业品牌制药公司Endo International plc（McKinsey）担任越来越重要的职务，最近担任该公司财务Vice President，2016年12月至2018年3月，企业FP&A和国际制药部门首席财务官。在此之前，他是Endo&8217；S.U.Brand Pharmaceuticals分部的财务、首席财务官Vice President。在加入Endo之前，Degnan先生从2004年开始在AstraZeneca PLC（一家全球生物制药公司）担任越来越重要的职务，最近从2013年7月到2014年11月担任美国商业金融高级财务总监。他是宾夕法尼亚州的一名注册会计师，自愿不活跃状态。Degnan先生拥有圣母大学（University of Notre Dame）会计学B.S.学位。
- Chris Degnan,Prior to joining UroGen, Mr. Degnan served as the Chief Financial Officer of Galera Therapeutics, Inc., a public, late-stage biopharmaceutical company focused on oncology, from October 2019 to August 2024. Prior to Galera, Mr. Degnan served as the Chief Financial Officer of Verrica Pharmaceuticals Inc., a public, biotechnology company focused on medical dermatology, from March 2018 to October 2019. Prior to Verrica, Mr. Degnan held roles of increasing responsibility at Endo International plc, a generics and specialty branded pharmaceutical company, beginning in November 2014. At Endo, Mr. Degnan most recently served as the Vice President of Finance, Corporate FP&A and International Pharmaceuticals Segment Chief Financial Officer from December 2016 to March 2018. Prior to that, he served as the Vice President of Finance, Chief Financial Officer for Endo's U.S. Branded Pharmaceuticals segment from March 2016 to December 2016, and as the Senior Finance Director, U.S. Branded Pharmaceuticals from November 2014 to March 2016. Prior to joining Endo, Mr. Degnan held roles of increasing responsibility at AstraZeneca plc, a global biopharmaceutical company, beginning in 2004. At AstraZeneca, Mr. Degnan most recently served as Senior Finance Director, U.S. Commercial Finance from July 2013 to November 2014. Mr. Degnan is a Certified Public Accountant in the State of Pennsylvania (voluntary inactive status) and holds a B.B.A. degree in Accountancy from the University of Notre Dame.
- Elizabeth Barrett
Elizabeth Barrett，自2019年1月起担任乌龙制药有限公司董事和乌龙制药有限公司总裁兼首席执行官。在加入UroGen之前，Barrett女士自2018年2月起担任诺华肿瘤学首席执行官和诺华执行委员会成员。在加入诺华之前，巴雷特女士曾在辉瑞公司担任过各种领导职务，最近担任肿瘤学全球总裁，在此之前担任欧洲全球创新制药总裁、北美专业护理业务部总裁和美国肿瘤学区域总裁。在加入辉瑞之前，Barrett女士是Cephalon公司副总裁兼肿瘤业务部门总经理。Barrett女士在圣约瑟夫大学获得工商管理-市场营销硕士学位，在路易斯安那大学获得学士学位。Barrett女士目前还担任Sage Therapeutics公司和Allogene Therapeutics, Inc.的董事。
Elizabeth Barrett,Prior to joining UroGen, Ms. Barrett served as the Chief Executive Officer of Novartis Oncology and a member of the Novartis Executive Committee since February 2018. Prior to Novartis, Ms. Barrett served at Pfizer Inc. in various leadership capacities, most recently as the Global President of Oncology and, before that, as President of Global Innovative Pharma for Europe, President of the Specialty Care Business Unit for North America, and Regional President of United States Oncology. Prior to Pfizer, Ms. Barrett was Vice President and General Manager of the Oncology Business Unit at Cephalon Inc. Ms. Barrett received an M.B.A. degree in Business Administration-Marketing from Saint Joseph's University and a B.S. from the University of Louisiana. Ms. Barrett also currently serves on the boards of directors of Sage Therapeutics, Inc. (since 2019) and Allogene Therapeutics, Inc. (since 2021).- Elizabeth Barrett，自2019年1月起担任乌龙制药有限公司董事和乌龙制药有限公司总裁兼首席执行官。在加入UroGen之前，Barrett女士自2018年2月起担任诺华肿瘤学首席执行官和诺华执行委员会成员。在加入诺华之前，巴雷特女士曾在辉瑞公司担任过各种领导职务，最近担任肿瘤学全球总裁，在此之前担任欧洲全球创新制药总裁、北美专业护理业务部总裁和美国肿瘤学区域总裁。在加入辉瑞之前，Barrett女士是Cephalon公司副总裁兼肿瘤业务部门总经理。Barrett女士在圣约瑟夫大学获得工商管理-市场营销硕士学位，在路易斯安那大学获得学士学位。Barrett女士目前还担任Sage Therapeutics公司和Allogene Therapeutics, Inc.的董事。
- Elizabeth Barrett,Prior to joining UroGen, Ms. Barrett served as the Chief Executive Officer of Novartis Oncology and a member of the Novartis Executive Committee since February 2018. Prior to Novartis, Ms. Barrett served at Pfizer Inc. in various leadership capacities, most recently as the Global President of Oncology and, before that, as President of Global Innovative Pharma for Europe, President of the Specialty Care Business Unit for North America, and Regional President of United States Oncology. Prior to Pfizer, Ms. Barrett was Vice President and General Manager of the Oncology Business Unit at Cephalon Inc. Ms. Barrett received an M.B.A. degree in Business Administration-Marketing from Saint Joseph's University and a B.S. from the University of Louisiana. Ms. Barrett also currently serves on the boards of directors of Sage Therapeutics, Inc. (since 2019) and Allogene Therapeutics, Inc. (since 2021).
- Mark P. Schoenberg
Mark P. Schoenberg，自2017年12月起担任乌龙制药有限公司首席医疗官，在此之前，自2016年2月起担任乌龙制药有限公司医疗总监。勋伯格博士在临床实践和研究方面拥有超过20年的经验，专注于各种形式的膀胱癌患者的护理。自2014年4月以来，勋伯格博士一直担任Yeshiva大学阿尔伯特·爱因斯坦医学院Montefiore医学中心泌尿外科教授和主任。在加入Montefiore之前，从2005年到2014年，Schoenberg博士曾担任约翰霍普金斯医院泌尿肿瘤学主任和Bernard L. Schwartz泌尿肿瘤学特聘教授。勋伯格博士还是膀胱癌倡导网络医学顾问委员会的前任主席、《膀胱癌生存指南》一书的作者、《膀胱癌教科书》的联合编辑、坎贝尔大学泌尿外科的撰稿人，以及《泌尿肿瘤学研讨会》杂志的前任高级编辑。勋伯格博士在得克萨斯大学Health Sciences中心获得了医学博士学位（阿尔法Omega Alpha），并在宾夕法尼亚大学医院完成了普通外科和泌尿外科住院医师的工作，在那里他担任了首席住院医师和泌尿外科讲师，之后在美国癌症协会的赞助下在约翰霍普金斯大学完成了基础研究和临床泌尿肿瘤学奖学金。勋伯格博士是美国外科医生学会的研究员，也是美国癌症研究协会、泌尿肿瘤学会和美国泌尿学会的成员。
Mark P. Schoenberg,has over 20 years of experience in clinical practice and research focused on the care of patients with all forms of bladder cancer. Since April 2014, Dr. Schoenberg has been University Professor and Chair of the Urology Department at The Montefiore Medical Center for The Albert Einstein College of Medicine of Yeshiva University. Prior to joining Montefiore, from 2005 to 2014, Dr. Schoenberg served as Director of Urologic Oncology and Bernard L. Schwartz Distinguished Professor of Urologic Oncology at Johns Hopkins Hospital. Dr. Schoenberg is also the past chair of the Medical Advisory Board of the Bladder Cancer Advocacy Network, the author of The Guide to Living with Bladder Cancer, co-editor of The Textbook of Bladder Cancer, a contributor to Campbell's Urology and a past Senior Editor of the journal Seminars in Urologic Oncology. Dr. Schoenberg received his M.D. (Alpha Omega Alpha) from the University of Texas Health Sciences Center and completed his residency in General Surgery and Urology at the Hospital of The University of Pennsylvania, where he served as chief resident and urology instructor, before completing basic research and clinical urologic oncology fellowships at Johns Hopkins under the auspices of The American Cancer Society. Dr. Schoenberg is a fellow of the American College of Surgeons, as well as a member of the American Association of Cancer Research, the Society of Urologic Oncology and the American Urological Association.- Mark P. Schoenberg，自2017年12月起担任乌龙制药有限公司首席医疗官，在此之前，自2016年2月起担任乌龙制药有限公司医疗总监。勋伯格博士在临床实践和研究方面拥有超过20年的经验，专注于各种形式的膀胱癌患者的护理。自2014年4月以来，勋伯格博士一直担任Yeshiva大学阿尔伯特·爱因斯坦医学院Montefiore医学中心泌尿外科教授和主任。在加入Montefiore之前，从2005年到2014年，Schoenberg博士曾担任约翰霍普金斯医院泌尿肿瘤学主任和Bernard L. Schwartz泌尿肿瘤学特聘教授。勋伯格博士还是膀胱癌倡导网络医学顾问委员会的前任主席、《膀胱癌生存指南》一书的作者、《膀胱癌教科书》的联合编辑、坎贝尔大学泌尿外科的撰稿人，以及《泌尿肿瘤学研讨会》杂志的前任高级编辑。勋伯格博士在得克萨斯大学Health Sciences中心获得了医学博士学位（阿尔法Omega Alpha），并在宾夕法尼亚大学医院完成了普通外科和泌尿外科住院医师的工作，在那里他担任了首席住院医师和泌尿外科讲师，之后在美国癌症协会的赞助下在约翰霍普金斯大学完成了基础研究和临床泌尿肿瘤学奖学金。勋伯格博士是美国外科医生学会的研究员，也是美国癌症研究协会、泌尿肿瘤学会和美国泌尿学会的成员。
- Mark P. Schoenberg,has over 20 years of experience in clinical practice and research focused on the care of patients with all forms of bladder cancer. Since April 2014, Dr. Schoenberg has been University Professor and Chair of the Urology Department at The Montefiore Medical Center for The Albert Einstein College of Medicine of Yeshiva University. Prior to joining Montefiore, from 2005 to 2014, Dr. Schoenberg served as Director of Urologic Oncology and Bernard L. Schwartz Distinguished Professor of Urologic Oncology at Johns Hopkins Hospital. Dr. Schoenberg is also the past chair of the Medical Advisory Board of the Bladder Cancer Advocacy Network, the author of The Guide to Living with Bladder Cancer, co-editor of The Textbook of Bladder Cancer, a contributor to Campbell's Urology and a past Senior Editor of the journal Seminars in Urologic Oncology. Dr. Schoenberg received his M.D. (Alpha Omega Alpha) from the University of Texas Health Sciences Center and completed his residency in General Surgery and Urology at the Hospital of The University of Pennsylvania, where he served as chief resident and urology instructor, before completing basic research and clinical urologic oncology fellowships at Johns Hopkins under the auspices of The American Cancer Society. Dr. Schoenberg is a fellow of the American College of Surgeons, as well as a member of the American Association of Cancer Research, the Society of Urologic Oncology and the American Urological Association.
- Jason Smith
Jason Smith，自2020年8月起担任乌龙制药有限公司总法律顾问、首席合规官和公司秘书。史密斯先生负责领导乌龙制药有限公司的法律、知识产权和公司合规职能。史密斯先生从辉瑞加入乌龙制药有限公司，并于2016年8月至2020年8月担任肿瘤学首席法律顾问。从2009年10月至2016年8月，史密斯先生担任辉瑞几项业务的法律顾问，包括疫苗和基本健康。在加入辉瑞之前，史密斯先生从2001年12月到2009年10月被辉瑞收购，一直在惠氏公司的法律部门工作，包括担任美国制药公司的反垄断法律顾问、全球产品法律顾问和首席法律顾问。在加入惠氏公司之前，史密斯先生于1998年9月至2001年12月在华盛顿特区的Howrey，Simon，Arnold & White担任反垄断和商业诉讼集团的合伙人。史密斯先生曾于1997年8月至1998年8月为尊敬的罗伯特·E·佩恩美国弗吉尼亚州东区联邦地区法院里士满分部担任书记员。史密斯先生在宾厄姆顿大学获得经济学学士学位，在乔治华盛顿大学法学院获得法学博士学位。
Jason Smith,joined Urogen Pharma Ltd. from Pfizer Inc., where he served as Chief Counsel, Oncology from August 2016 to August 2020. Prior to Pfizer, Mr. Smith worked in the legal department at Wyeth in a variety of roles including as antitrust counsel, Global Product Counsel and Chief Counsel, U.S. Pharmaceuticals, leading a team of lawyers supporting the prescription pharmaceuticals businesses. Before joining Wyeth, Mr. Smith was an associate at Howrey, Simon, Arnold & White in Washington, DC, in the antitrust and commercial litigation groups. Mr. Smith received his bachelor's degree in Economics, cum laude from Binghamton University and his juris doctor degree, with high honors, from George Washington University.- Jason Smith，自2020年8月起担任乌龙制药有限公司总法律顾问、首席合规官和公司秘书。史密斯先生负责领导乌龙制药有限公司的法律、知识产权和公司合规职能。史密斯先生从辉瑞加入乌龙制药有限公司，并于2016年8月至2020年8月担任肿瘤学首席法律顾问。从2009年10月至2016年8月，史密斯先生担任辉瑞几项业务的法律顾问，包括疫苗和基本健康。在加入辉瑞之前，史密斯先生从2001年12月到2009年10月被辉瑞收购，一直在惠氏公司的法律部门工作，包括担任美国制药公司的反垄断法律顾问、全球产品法律顾问和首席法律顾问。在加入惠氏公司之前，史密斯先生于1998年9月至2001年12月在华盛顿特区的Howrey，Simon，Arnold & White担任反垄断和商业诉讼集团的合伙人。史密斯先生曾于1997年8月至1998年8月为尊敬的罗伯特·E·佩恩美国弗吉尼亚州东区联邦地区法院里士满分部担任书记员。史密斯先生在宾厄姆顿大学获得经济学学士学位，在乔治华盛顿大学法学院获得法学博士学位。
- Jason Smith,joined Urogen Pharma Ltd. from Pfizer Inc., where he served as Chief Counsel, Oncology from August 2016 to August 2020. Prior to Pfizer, Mr. Smith worked in the legal department at Wyeth in a variety of roles including as antitrust counsel, Global Product Counsel and Chief Counsel, U.S. Pharmaceuticals, leading a team of lawyers supporting the prescription pharmaceuticals businesses. Before joining Wyeth, Mr. Smith was an associate at Howrey, Simon, Arnold & White in Washington, DC, in the antitrust and commercial litigation groups. Mr. Smith received his bachelor's degree in Economics, cum laude from Binghamton University and his juris doctor degree, with high honors, from George Washington University.
- Chris Degnan
Chris Degnan，在加入UroGen之前，Degnan先生于2019年10月至2024年8月期间，担任Galera Therapeutics, Inc.（一家专注于肿瘤学的上市晚期生物制药公司）的首席财务官。在加入Galera之前，Degnan先生于2018年3月至2019年10月在Verrica Pharmaceuticals Inc.（一家上市的生物技术公司，专注于医学皮肤病学）担任首席财务官。在加入Verrica之前，Degnan先生于2014年11月开始在仿制药和专业品牌制药公司远藤制药 plc担任越来越重要的职务。在Endo，Degnan先生最近于2016年12月至2018年3月担任财务、企业FP & A和国际制药部门的副总裁首席财务官。在此之前，他于2016年3月至2016年12月担任Endo美国品牌制药部门的财务副总裁、首席财务官，并于2014年11月至2016年3月担任美国品牌制药高级财务总监。在加入Endo之前，Degnan先生于2004年开始在全球生物制药公司阿斯利康 PLC担任越来越多的职务。在阿斯利康，Degnan先生最近于2013年7月至2014年11月担任美国商业金融高级财务总监。Degnan先生是宾夕法尼亚州的注册会计师（自愿非活动状态），并拥有圣母大学会计学学士学位。
Chris Degnan,Prior to joining UroGen, Mr. Degnan served as the Chief Financial Officer of Galera Therapeutics, Inc., a public, late-stage biopharmaceutical company focused on oncology, from October 2019 to August 2024. Prior to Galera, Mr. Degnan served as the Chief Financial Officer of Verrica Pharmaceuticals Inc., a public, biotechnology company focused on medical dermatology, from March 2018 to October 2019. Prior to Verrica, Mr. Degnan held roles of increasing responsibility at Endo International plc, a generics and specialty branded pharmaceutical company, beginning in November 2014. At Endo, Mr. Degnan most recently served as the Vice President of Finance, Corporate FP&A and International Pharmaceuticals Segment Chief Financial Officer from December 2016 to March 2018. Prior to that, he served as the Vice President of Finance, Chief Financial Officer for Endo's U.S. Branded Pharmaceuticals segment from March 2016 to December 2016, and as the Senior Finance Director, U.S. Branded Pharmaceuticals from November 2014 to March 2016. Prior to joining Endo, Mr. Degnan held roles of increasing responsibility at AstraZeneca plc, a global biopharmaceutical company, beginning in 2004. At AstraZeneca, Mr. Degnan most recently served as Senior Finance Director, U.S. Commercial Finance from July 2013 to November 2014. Mr. Degnan is a Certified Public Accountant in the State of Pennsylvania (voluntary inactive status) and holds a B.B.A. degree in Accountancy from the University of Notre Dame.- Chris Degnan，在加入UroGen之前，Degnan先生于2019年10月至2024年8月期间，担任Galera Therapeutics, Inc.（一家专注于肿瘤学的上市晚期生物制药公司）的首席财务官。在加入Galera之前，Degnan先生于2018年3月至2019年10月在Verrica Pharmaceuticals Inc.（一家上市的生物技术公司，专注于医学皮肤病学）担任首席财务官。在加入Verrica之前，Degnan先生于2014年11月开始在仿制药和专业品牌制药公司远藤制药 plc担任越来越重要的职务。在Endo，Degnan先生最近于2016年12月至2018年3月担任财务、企业FP & A和国际制药部门的副总裁首席财务官。在此之前，他于2016年3月至2016年12月担任Endo美国品牌制药部门的财务副总裁、首席财务官，并于2014年11月至2016年3月担任美国品牌制药高级财务总监。在加入Endo之前，Degnan先生于2004年开始在全球生物制药公司阿斯利康 PLC担任越来越多的职务。在阿斯利康，Degnan先生最近于2013年7月至2014年11月担任美国商业金融高级财务总监。Degnan先生是宾夕法尼亚州的注册会计师（自愿非活动状态），并拥有圣母大学会计学学士学位。
- Chris Degnan,Prior to joining UroGen, Mr. Degnan served as the Chief Financial Officer of Galera Therapeutics, Inc., a public, late-stage biopharmaceutical company focused on oncology, from October 2019 to August 2024. Prior to Galera, Mr. Degnan served as the Chief Financial Officer of Verrica Pharmaceuticals Inc., a public, biotechnology company focused on medical dermatology, from March 2018 to October 2019. Prior to Verrica, Mr. Degnan held roles of increasing responsibility at Endo International plc, a generics and specialty branded pharmaceutical company, beginning in November 2014. At Endo, Mr. Degnan most recently served as the Vice President of Finance, Corporate FP&A and International Pharmaceuticals Segment Chief Financial Officer from December 2016 to March 2018. Prior to that, he served as the Vice President of Finance, Chief Financial Officer for Endo's U.S. Branded Pharmaceuticals segment from March 2016 to December 2016, and as the Senior Finance Director, U.S. Branded Pharmaceuticals from November 2014 to March 2016. Prior to joining Endo, Mr. Degnan held roles of increasing responsibility at AstraZeneca plc, a global biopharmaceutical company, beginning in 2004. At AstraZeneca, Mr. Degnan most recently served as Senior Finance Director, U.S. Commercial Finance from July 2013 to November 2014. Mr. Degnan is a Certified Public Accountant in the State of Pennsylvania (voluntary inactive status) and holds a B.B.A. degree in Accountancy from the University of Notre Dame.